Molecular insights into Parkinson's disease

F1000 Medicine Reports

Volumn 3, Issue 1, 2011, Pages

  Thomas, Bobby ^a   Beal, M Flint ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (3,5 DIBROMO 4 HYDROXYBENZYLIDENE) 1,3 DIHYDRO 5 IODO 2 INDOLONE; ALPHA SYNUCLEIN; APOMORPHINE; DJ 1 PROTEIN; INDIRUBIN; INDIRUBIN 3' MONOXIME; LEUCINE RICH REPEAT KINASE 2; LEVODOPA; PARKIN; PHOSPHOTRANSFERASE; PTEN INDUCED PUTATIVE KINASE 1; UNCLASSIFIED DRUG;

AUTONOMIC DYSFUNCTION; BRAIN PROTECTION; DOPAMINERGIC NERVE CELL; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; MESENCEPHALON; MOTOR DYSFUNCTION; NONHUMAN; PARKINSON DISEASE; REVIEW;

EID: 79955695259     PISSN: None     EISSN: 17575931     Source Type: Journal    
DOI: 10.3410/M3-7     Document Type: Review

References (68)

1. Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, Nelson LM: Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003, 157:1015-22. (Pubitemid 36628805)
2. Thomas B: Parkinson's disease: from molecular pathways in disease to therapeutic approaches. Antioxid Redox Signal 2009, 11:2077-82.
3. Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, Kubo M, Kawaguchi T, Tsunoda T, Watanabe M, Takeda A, Tomiyama H, Nakashima K, Hasegawa K, Obata F, Yoshikawa T, Kawakami H, Sakoda S, Yamamoto M, Hattori N, Murata M, Nakamura Y, Toda T: Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet 2009, 41:1303-7. F1000 Factor 8 Evaluated by X William Yang 01 Dec 2009
4. Simón-Sánchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, Paisan-Ruiz C, Lichtner P, Scholz SW, Hernandez DG, Krüger R, Federoff M, Klein C, Goate A, Perlmutter J, Bonin M, Nalls MA, Illig T, Gieger C, Houlden H, Steffens M, Okun MS, Racette BA, Cookson MR, Foote KD, Fernandez HH, Traynor BJ, Schreiber S, Arepalli S, Zonozi R, et al.: Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 2009, 41:1308-12. F1000 Factor 8 Evaluated by X William Yang 01 Dec 2009
5. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL: Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-7. (Pubitemid 27443610)
6. Krüger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kösel S, Przuntek H, Epplen JT, Schols L, Riess O: Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998, 18:106-8.
7. Zarranz JJ, Alegre J, Gómez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atarés B, Llorens V, Gomez Tortosa E, del Ser T, Muñoz DG, de Yebenes JG: The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004, 55:164-73. F1000 Factor 8 Evaluated by Thomas Gasser 18 Feb 2004, John Hardy 22 Mar 2004, Albert La Spada 21 Apr 2004
8. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K: alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003, 302:841. F1000 Factor 9 Evaluated by Sue Malcolm 16 Dec 2003, Vicky Brandt 19 Dec 2003
9. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, Levecque C, Larvor L, Andrieux J, Hulihan M, Waucquier N, Defebvre L, Amouyel P, Farrer M, Destée A: Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004, 364:1167-9. (Pubitemid 39296604)
10. Ibáñez P, Bonnet AM, Débarges B, Lohmann E, Tison F, Pollak P, Agid Y, Dürr A, Brice A: Causal relation between alphasynuclein gene duplication and familial Parkinson's disease. Lancet 2004, 364:1169-71. (Pubitemid 39296605)
11. Winkler S, Hagenah J, Lincoln S, Heckman M, Haugarvoll K, Lohmann-Hedrich K, Kostic V, Farrer M, Klein C: alpha-Synuclein and Parkinson disease susceptibility. Neurology 2007, 69:1745-50.
12. Lee VM, Trojanowski JQ: Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery. Neuron 2006, 52:33-8. (Pubitemid 44479831)
13. Tanaka M, Kim YM, Lee G, Junn E, Iwatsubo T, Mouradian MM: Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J Biol Chem 2004, 279:4625-31. (Pubitemid 38199054)
14. Zhou W, Freed CR: DJ-1 up-regulates glutathione synthesis during oxidative stress and inhibits A53T alpha-synuclein toxicity. J Biol Chem 2005, 280:43150-8. (Pubitemid 43049281)
15. Feany MB, Bender WW: A Drosophila model of Parkinson's disease. Nature 2000, 404:394-8. (Pubitemid 30164341)
16. Periquet M, Fulga T, Myllykangas L, Schlossmacher MG, Feany MB: Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo. J Neurosci 2007, 27:3338-46. (Pubitemid 46474139)
17. St Martin JL, Klucken J, Outeiro TF, Nguyen P, Keller-McGandy C, Cantuti-Castelvetri I, Grammatopoulos TN, Standaert DG, Hyman BT, McLean PJ: Dopaminergic neuron loss and upregulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra. J Neurochem 2007, 100:1449-57. (Pubitemid 46376202)
18. Kirik D, Annett LE, Burger C, Muzyczka N, Mandel RJ, Björklund A: Nigrostriatal alpha-synucleinopathy induced by viral vectormediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proc Natl Acad Sci U S A 2003, 100:2884-9. (Pubitemid 36297593)
19. Banerjee R, Starkov AA, Beal MF, Thomas B: Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis. Biochim Biophys Acta 2009, 1792:651-63.
20. Furukawa K, Matsuzaki-Kobayashi M, Hasegawa T, Kikuchi A, Sugeno N, Itoyama Y, Wang Y, Yao PJ, Bushlin I, Takeda A: Plasma membrane ion permeability induced by mutant alphasynuclein contributes to the degeneration of neural cells. J Neurochem 2006, 97:1071-7.
21. Nakamura K, Nemani VM, Wallender EK, Kaehlcke K, Ott M, Edwards RH: Optical reporters for the conformation of alphasynuclein reveal a specific interaction with mitochondria. J Neurosci 2008, 28:12305-17.
22. Hsu LJ, Sagara Y, Arroyo A, Rockenstein E, Sisk A, Mallory M, Wong J, Takenouchi T, Hashimoto M, Masliah E: alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol 2000, 157:401-10. (Pubitemid 30627559)
23. Martin LJ, Pan Y, Price AC, Sterling W, Copeland NG, Jenkins NA, Price DL, Lee MK: Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J Neurosci 2006, 26:41-50. (Pubitemid 43089519)
24. Larsen KE, Schmitz Y, Troyer MD, Mosharov E, Dietrich P, Quazi AZ, Savalle M, Nemani V, Chaudhry FA, Edwards RH, Stefanis L, Sulzer D: Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J Neurosci 2006, 26:11915-22. (Pubitemid 44772102)
25. Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, Lee MK, Chaudhry FA, Nicoll RA, Edwards RH: Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 2010, 65:66-79. F1000 Factor 9 Evaluated by Jesse Hay 28 Jan 2010, Robert Burgoyne 29 Jan 2010
26. Lotharius J, Brundin P: Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat Rev Neurosci 2002, 3:932-42.
27. Snyder H, Mensah K, Theisler C, Lee J, Matouschek A, Wolozin B: Aggregated and monomeric alpha-synuclein bind to the S6' proteasomal protein and inhibit proteasomal function. J Biol Chem 2003, 278:11753-9. (Pubitemid 36800143)
28. Stefanis L, Larsen KE, Rideout HJ, Sulzer D, Greene LA: Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J Neurosci 2001, 21:9549-60. (Pubitemid 34184043)
29. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D: Impaired degradation of mutant alpha-synuclein by chaperone- mediated autophagy. Science 2004, 305:1292-5. F1000 Factor 6 Evaluated by Daniel Klionsky 09 Sep 2004
30. Cooper AA, Gitler AD, Cashikar A, Haynes CM, Hill KJ, Bhullar B, Liu K, Xu K, Strathearn KE, Liu F, Cao S, Caldwell KA, Caldwell GA, Marsischky G, Kolodner RD, Labaer J, Rochet JC, Bonini NM, Lindquist S: Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 2006, 313:324-8. F1000 Factor 21 Evaluated by Ted Dawson 30 Jun 2006, Adam Linstedt 31 Jul 2006, Nektarios Tavernarakis 01 Aug 2006, Alain Prochiantz 15 Aug 2006, Monte Gates 21 Aug 2006, Ruth Collins 14 Feb 2007, Jesse Hay 09 Mar 2007
31. Thayanidhi N, Helm JR, Nycz DC, Bentley M, Liang Y, Hay JC: Alpha-synuclein delays endoplasmic reticulum (ER)-to-Golgi transport in mammalian cells by antagonizing ER/Golgi SNAREs. Mol Biol Cell 2010, 21:1850-63.
32. West AB, Moore DJ, Choi C, Andrabi SA, Li X, Dikeman D, Biskup S, Zhang Z, Lim KL, Dawson VL, Dawson TM: Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet 2007, 16:223-32. (Pubitemid 46179004)
33. Greggio E, Jain S, Kingsbury A, Bandopadhyay R, Lewis P, Kaganovich A, van der Brug MP, Beilina A, Blackinton J, Thomas KJ, Ahmad R, Miller DW, Kesavapany S, Singleton A, Lees A, Harvey RJ, Harvey K, Cookson MR: Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 2006, 23:329-41. (Pubitemid 44097032)
34. Smith WW, Pei Z, Jiang H, Dawson VL, Dawson TM, Ross CA: Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 2006, 9:1231-3. (Pubitemid 44454261)
35. MacLeod D, Dowman J, Hammond R, Leete T, Inoue K, Abeliovich A: The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 2006, 52:587-93. (Pubitemid 44781171)
36. Sakaguchi-Nakashima A, Meir JY, Jin Y, Matsumoto K, Hisamoto N: LRK-1, a C. elegans PARK8-related kinase, regulates axonaldendritic polarity of SV proteins. Curr Biol 2007, 17:592-8. (Pubitemid 46497793)
37. Imai Y, Gehrke S, Wang HQ, Takahashi R, Hasegawa K, Oota E, Lu B: Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J 2008, 27:2432-43.
38. Tain LS, Mortiboys H, Tao RN, Ziviani E, Bandmann O, Whitworth AJ: Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss. Nat Neurosci 2009, 12:1129-35.
39. Jaleel M, Nichols RJ, Deak M, Campbell DG, Gillardon F, Knebel A, Alessi DR: LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem J 2007, 405:307-17. (Pubitemid 47075166)
40. Tong Y, Pisani A, Martella G, Karouani M, Yamaguchi H, Pothos EN, Shen J: R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc Natl Acad Sci U S A 2009, 106:14622-7. F1000 Factor 8 Evaluated by Roger Barker 11 Mar 2010
41. Li Y, Liu W, Oo TF, Wang L, Tang Y, Jackson-Lewis V, Zhou C, Geghman K, Bogdanov M, Przedborski S, Beal MF, Burke RE, Li C: Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci 2009, 12:826-8. F1000 Factor 6 Evaluated by Roger Barker 11 Mar 2010
42. Lin X, Parisiadou L, Gu XL, Wang L, Shim H, Sun L, Xie C, Long CX, Yang WJ, Ding J, Chen ZZ, Gallant PE, Tao-Cheng JH, Rudow G, Troncoso JC, Liu Z, Li Z, Cai H: Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron 2009, 64:807-27.
43. Lee BD, Shin JH, VanKampen J, Petrucelli L, West AB, Ko HS, Lee YI, Maguire-Zeiss KA, Bowers WJ, Federoff HJ, Dawson VL, Dawson TM: Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat Med 2010, 16:998-1000. F1000 Factor 6 Evaluated by George Ricaurte 22 Oct 2010
44. Dodson MW, Guo M: Pink1, Parkin, DJ-1 and mitochondrial dysfunction in Parkinson's disease. Curr Opin Neurobiol 2007, 17:331-7. (Pubitemid 46880329)
45. Mata IF, Lockhart PJ, Farrer MJ: Parkin genetics: one model for Parkinson's disease. Hum Mol Genet 2004, 13(Suppl 1):R127-133.
46. Gasser T: Mendelian forms of Parkinson's disease. Biochim Biophys Acta 2009, 1792:587-96.
47. Heutink P: PINK-1 and DJ-1-new genes for autosomal recessive Parkinson's disease. J Neural Transm Suppl 2006, 70:215-219.
48. Dawson TM, Dawson VL: The role of parkin in familial and sporadic Parkinson's disease. Mov Disord 2010, 25(Suppl 1): S32-39.
49. Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S, Ali Z, Del Turco D, Bentivoglio AR, Healy DG, Albanese A, Nussbaum R, González-Maldonado R, Deller T, Salvi S, Cortelli P, Gilks WP, Latchman DS, Harvey RJ, Dallapiccola B, Auburger G, Wood NW: Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004, 304:1158-60. F1000 Factor 10 Evaluated by M Flint Beal 05 May 2004, Michele Ramsay 16 Aug 2004
50. Silvestri L, Caputo V, Bellacchio E, Atorino L, Dallapiccola B, Valente EM, Casari G: Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. Hum Mol Genet 2005, 14:3477-92. (Pubitemid 41672130)
51. Zhou C, Huang Y, Shao Y, May J, Prou D, Perier C, Dauer W, Schon EA, Przedborski S: The kinase domain of mitochondrial PINK1 faces the cytoplasm. Proc Natl Acad Sci U S A 2008, 105:12022-7.
52. Greene JC, Whitworth AJ, Kuo I, Andrews LA, Feany MB, Pallanck LJ: Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc Natl Acad Sci U S A 2003, 100:4078-83. (Pubitemid 36418160)
53. Pesah Y, Pham T, Burgess H, Middlebrooks B, Verstreken P, Zhou Y, Harding M, Bellen H, Mardon G: Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress. Development 2004, 131:2183-94. (Pubitemid 38702049)
54. Clark IE, Dodson MW, Jiang C, Cao JH, Huh JR, Seol JH, Yoo SJ, Hay BA, Guo M: Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 2006, 441:1162-6. F1000 Factor 10 Evaluated by M Flint Beal 03 Aug 2006, Michael Ehlers 21 Nov 2006
55. Palacino JJ, Sagi D, Goldberg MS, Krauss S, Motz C, Wacker M, Klose J, Shen J: Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 2004, 279:18614-22. F1000 Factor 8 Evaluated byThomas Gasser 31 Mar 2004
56. Gautier CA, Kitada T, Shen J: Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress. Proc Natl Acad Sci U S A 2008, 105:11364-9.
57. Park J, Lee SB, Lee S, Kim Y, Song S, Kim S, Bae E, Kim J, Shong M, Kim JM, Chung J: Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 2006, 441:1157-61. F1000 Factor 12 Evaluated by Monte Gates 30 May 2006, M Flint Beal 03 Aug 2006, Michael Ehlers 21 Nov 2006
58. Narendra D, Tanaka A, Suen DF, Youle RJ: Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol 2008, 183:795-803. F1000 Factor 9 Evaluated by Kenneth Downing 09 Dec 2008, Robert Parton 16 Dec 2008
59. Vives-Bauza C, Zhou C, Huang Y, Cui M, de Vries RL, Kim J, May J, Tocilescu MA, Liu W, Ko HS, Magrané J, Moore DJ, Dawson VL, Grailhe R, Dawson TM, Li C, Tieu K, Przedborski S: PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proc Natl Acad Sci U S A 2010, 107:378-83. F1000 Factor 6 Evaluated by Massimo Zeviani 11 Feb 2010
60. Macedo MG, Anar B, Bronner IF, Cannella M, Squitieri F, Bonifati V, Hoogeveen A, Heutink P, Rizzu P: The DJ-1L166P mutant protein associated with early onset Parkinson's disease is unstable and forms higher-order protein complexes. Hum Mol Genet 2003, 12:2807-16. (Pubitemid 37407117)
61. Moore DJ, Dawson VL, Dawson TM: Genetics of Parkinson's disease: what do mutations in DJ-1 tell us? Ann Neurol 2003, 54:281-2.
62. Cookson MR, Bandmann O: Parkinson's disease: insights from pathways. Hum Mol Genet 2010, 19:R21-27.
63. Kahle PJ, Waak J, Gasser T: DJ-1 and prevention of oxidative stress in Parkinson's disease and other age-related disorders. Free Radic Biol Med 2009, 47:1354-61.
64. Andres-Mateos E, Perier C, Zhang L, Blanchard-Fillion B, Greco TM, Thomas B, Ko HS, Sasaki M, Ischiropoulos H, Przedborski S, Dawson TM, Dawson VL: DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proc Natl Acad Sci U S A 2007, 104:14807-12. (Pubitemid 350003224)
65. Aleyasin H, Rousseaux MW, Marcogliese PC, Hewitt SJ, Irrcher I, Joselin AP, Parsanejad M, Kim RH, Rizzu P, Callaghan SM, Slack RS, Mak TW, Park DS: DJ-1 protects the nigrostriatal axis from the neurotoxin MPTP by modulation of the AKT pathway. Proc Natl Acad Sci U S A 2010, 107:3186-91. F1000 Factor 8 Evaluated by M Flint Beal 11 Feb 2010
66. Irrcher I, Aleyasin H, Seifert EL, Hewitt SJ, Chhabra S, Phillips M, Lutz AK, Rousseaux MW, Bevilacqua L, Jahani-Asl A, Callaghan S, MacLaurin JG, Winklhofer KF, Rizzu P, Rippstein P, Kim RH, Chen CX, Fon EA, Slack RS, Harper ME, McBride HM, Mak TW, Park DS: Loss of the Parkinson's disease-linked gene DJ-1 perturbs mitochondrial dynamics. Hum Mol Genet 2010, 19:3734-46.
67. Krebiehl G, Ruckerbauer S, Burbulla LF, Kieper N, Maurer B, Waak J, Wolburg H, Gizatullina Z, Gellerich FN, Woitalla D, Riess O, Kahle PJ, Proikas-Cezanne T, Krüger R: Reduced basal autophagy and impaired mitochondrial dynamics due to loss of Parkinson's disease-associated protein DJ-1. PLoS One 2010, 5:e9367.
68. Thomas B, Beal MF: Parkinson's disease. Hum Mol Genet 2007, 16(Suppl 2):R183-94.